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Abstract
Background: Staphylococcus aureus particularly MRSA strains are one of the major causes of community and
hospital acquired bacterial infections. They are also becoming increasingly multi-drug resistant and have recently
developed resistance to vancomycin, which has been used successfully to treat MRSA for many years. In-vitro
determination of drug resistance patterns of S. aureus is critical for the selection of effective drugs for the treatment
of staphylococci infections.
The main aim of this study was to determine the prevalence of methicillin resistant S. aureus strains from different
clinical specimens from patients referred for routine culture and sensitivity testing.
Method: A cross sectional study was conducted among 1360 participants at Yekatit 12 Hospital Medical College in
Ethiopia from September 2013 to April 2014. Clinical samples from various anatomical sites of study participants
were cultured on blood agar and mannitol salt agar and identified to be S. aureus by using catalase, coagulase and
DNAse tests. S. aureus isolates then were screened for MRSA using 30 μg cefoxitin disc and other 11 antimicrobial
drugs by disc diffusion procedure, and agar dilution and E tests for vancomycin. All S. aureus isolates examined for
beta-lactamase production by employing nitrocefin. Data were analyzed using SPSS version 20 software and logistic
regressions were applied to assess any association between dependent and independent variables.
Results: Of 1360 clinical specimens analyzed S. aureus was recovered from (194, 14.3 %). Rate of isolation of S.
aureus with regard to clinical specimens was the highest in pus (118, 55.4 %).No S. aureus was isolated from CSF
and urethral discharge. Out of 194 S. aureus isolates, (34, 17.5 %) were found out to be MRSA and the remaining
(160, 82.5 %) were MSSA. Ninety eight (50.5 %) S. aureus were multi drug resistant and the highest isolates were
resistant to penicillin (187, 96.4 %) and least resistant for clindamycin (23, 11.9 %) and vancomycin (10, 5.1 %). MRSA
strains were 100 % resistant to penicillin G, erythromycin, trimethoprim-sulfamethoxazole and least resistant to
vancomycin (10, 29.4 %). Out of 194 S. aureus isolates (153, 79.0 %) were beta-lactamase producers.
Conclusion: In this study S. aureus isolates exhibited very high degree of resistance to different antibiotics. The
isolates were also multidrug resistant to several combinations of the tested antibiotics. The emergence of
vancomycin resistant S. aureus highlights the value of prudent prescribing of antibiotics and avoiding their irrational use.
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Background
Staphylococcal infections still remain an important cause
of mortality and morbidity worldwide despite the devel-
opment of antimicrobial agents. Among the staphylococ-
cus species, Staphylococcus aureus is the most virulent
species of the genus causing both nosocomial and com-
munity acquired infections worldwide [1]. The organism
has been found to be the most common bacterial agent
recovered from blood stream infections, skin and soft
tissue infections, pneumonia and hospital acquired post
operative wound infections [2]. Changes in the drug
susceptibility profile of S. aureus have been reported
worldwide; thereby making treating infections caused by
S. aureus more difficult [3–5].
Dramatic changes in the susceptibility of S. aureus to
beta-lactam antibiotics particularly to penicillin and
cephalosporin in both hospital and community settings
have been reported worldwide [6]. Several mechanisms
for the development of MRSA have been reported.
Among these production of a unique penicillin-binding
protein (PBP) that has a low affinity for β-lactam antibi-
otics and whose effects are determined by several struc-
tural genes (e.g., mecR1 and mecI) [7, 8], production of
the usual PBPs, but with modified affinities for β-lactam
drugs, and production of penicillinase enzyme are most
important ones [9].
MRSA spreads more readily than other strains once
introduced into hospitals, and are often difficult to eradi-
cate once established. In some countries MRSA make up
to 75 % of all S. aureus isolates in hospitals [10]. Trans-
mission of MRSA occurs primarily from colonized or in-
fected patients or staff to other patients or staff, or vice
versa [11]. Prevalence, however, varies markedly in hos-
pitals in the same country and from one country to an-
other. Furthermore, in Ethiopia, little information exists
regarding prevalence and drug susceptibility pattern of
methicillin resistant S. aureus isolated from various clin-
ical samples. Therefore, studies on the prevalence and
drug susceptibility patterns of S. aureus are of the high-
est priorities.
Methods
Study setting and context
A cross sectional study was conducted among 1360
study participants at Yekatit 12 Hospital Medical
College, Addis Ababa, Ethiopia from September 2013 to
April 2014. The hospital is a tertiary level referral and
teaching hospital which provides health care services to
patients in and around Addis Ababa, the capital city of
the country.
Specimen collection and processing
Clinical samples were collected from participants by
employing standard microbiological procedures. Nasal
swab, pus from wound, ear discharge, blood, throat
swab, eye swab, vaginal discharge, urethral discharge,
urine, stool, sputum, CSF and body fluids were clinical
specimens collected. All specimens were transported to
microbiology laboratory of the hospital with minimum
delay for culture and sensitivity tests.
Clinical specimens were inoculated onto blood agar
base (Oxoid, Basingstoke, Hampshire, England) to which
5 % sheep blood was added and mannitol salt agar
(Oxoid, Basingstoke, Hampshire, England) by using
streaking method. Inoculated plates were incubated at
35–37 °C for 18 to 24 h aerobically. Bacterial colonies
showing typical characteristics of S. aureus (i.e., beta
hemolytic on blood agar and colonies with golden yellow
pigmentation on mannitol salt agar) were subjected to
subculture on to basic media, gram stain and biochem-
ical tests catalase and coagulase. Catalase positive and
gram positive bacteria appearing in grape like cluster
was spot inoculated to DNase agar (Oxoid, Basingstoke,
Hampshire, England). Inoculated DNAse agar plates
were incubated at 37 °C over night and flooded with 1 N
HCl (Merk, Darmstadt, Germany). Isolates that hydro-
lyzed DNA in DNAse agar were considered S. aureus.
Antimicrobial susceptibility testing
Antimicrobial susceptibility test was carried out by Kirby
Bauer disc diffusion method as per Clinical Laboratory
Standards Institute (CLSI, 2013) guidelines on Muller
Hinton agar (Oxoid, Basingstoke, England) for 11 anti-
microbials [12]. The growth suspension was prepared in
0.5 ml of the same broth medium and the turbidity was
adjusted to match that of 0.5 McFarland standards to
obtain approximately the organism number of 1 × 106
colony forming units (CFU) per ml. A sterile swab was
dipped into the suspension and the excess of inoculum
was removed by pressing it against the sides of the tube.
Then the swab was applied to the center of Muller
Hinton agar plat and evenly spread on the medium.
Antibiotic discs were placed after 15 min of inoculation
to Muller Hinton agar seeded with each isolate and were
incubated for 24 h at 35–37 °C. The diameter of the
zone of inhibition around the disc was measured using
sliding metal caliper.
Vancomycin susceptibility test was done by agar dilu-
tion and E test (Epsilometer) techniques. Agar dilution
test involves the incorporation of varying concentrations
of vancomycin into an agar medium, using serial twofold
dilutions, followed by the application of a defined S.
aureus inoculum to the agar surface of the plate. These
results are interpreted based on determination of MIC
of vancomycin in μg/ml (usually 2 μg/ml to16μg/ml
concentration) for S. aureus. E test is manufactured
by biomerieux, consists of a predefined, continuous
and exponential gradient of antibiotic concentrations
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immobilized along a rectangular plastic test strip.
After 48 h incubation a drop-shaped inhibition zone
intersects the graded test strip at the inhibitory con-
centration of the antibiotic. Vancomycin resistant
strains were also checked in reference laboratory at EPHI
by Broth Microdilution (BMD) method before declaring
as resistant. In this broth microdilution, susceptibility
panel in 96-well microtiter plates were containing various
concentration of antimicrobial agents. Then, standardized
numbers of bacteria was inoculated into the wells of
96-well microtiter and incubate overnight at 35 °C.
The MIC value was observed as the lowest concentra-
tion where no viability was observed in the wells of
96-microwell plates after incubation [13].
Beta-lactamase production test
All S. aureus strains were screened for beta-lactamase
production by employing nitocefin, the procedures of
Efuntoye et al. [14]. Culture of each isolates was streaked
onto sticks impregnated with nitocefin a chromogenic
cephalosporin (Unipath Limited, Hampshire, England)
that produces a rapid color change from yellow to pink/
red when the beta-lactam ring is hydrolyzed by beta-
lactamase.
Ethical approval
The study was conducted after it was ethically reviewed
and approved by the Department of Research and
Ethical Review Committee of Department of Medical
Laboratory Sciences, College of Health Sciences, Addis
Ababa University. Ethical clearance was also obtained
from Addis Ababa Health Bureau. Then permission was
obtained from Yekatit 12 Hospital Medical College. In-
formed written consent was obtained from participants
before data collection. All the information obtained from
the study subjects were coded to maintain confidentially.
When the participants were found to be positive for
S. aureus, they were informed by the hospital clin-
ician and received proper treatment.
Definition of terms
MRSA is defined as zone of inhibition less than or equal
to 21 mm on MHA with 30 μg cefoxitin disc seeded
with growth suspension of S. aureus isolates adjusted to
0.5 McFarland standards [12].
MDR is defined as non-susceptibility to at least one
agent in three or more antimicrobial categories [13].
MIC is the lowest concentration of the antimicrobial
agent that inhibits visible growth of the organism after a
24-hour incubation period.
Statistical analysis and quality assurance
The reliability of the study findings were guaranteed by
implementing quality control measures throughout the
whole processes of laboratory work. S. aureus ATCC
25923 is a methicillin susceptible strain was used to
check the conditions were favorable for detection of re-
sistance. This strain was obtained from Ethiopian Public
Health Institute (EPHI). Data were coded, entered and
analyzed using SPSS software version 20 (SPSS INC,
Chicago, IL, USA). Binary logistic regression was used to
determine the association between S. aureus and clinical
specimens. Multivariate logistic regressions were used to
control confounding factors. P-values less than 0.05 were
taken as statistically significant.
Results
Socio-demographic characteristics of participants
A total of 1360 study participants were enrolled in the
present study of which (654, 48.1 %) were males and
(706, 51.9 %) females with a sex ratio of 0.93:1. The ages
of study subjects ranged from 1 month to 89 years
with a mean age of 23.4 ± 0.5 years and median age
Table 1 Association of S. aureus in study participants with regard to gender and age group at Yekatit 12 Hospital Medical College
from September 2013 to April 2014, Addis Ababa, Ethiopia
Variable Presence of S. aureus COR(95 % CI) P-value AOR(95 % CI) P-value
Yes (N/%) No (N/%)
Sex Male 106(16.2) 548(83.8) 0.73(0.54, 0.99) 0.049 1.05(0.72,1.53) 0.771
Female 88(12.5) 618(87.5) 1 - 1 -
Age group <1 9(8.6) 96(91.4) 1.47(0.55, 3.92) 0.434 - -
1–14 48(10.4) 413(89.6) 1.19(0.55, 2.54) 0.651 - -
15–24 46(21.0) 164(79.0) 0.49(0.23, 1.06) 0.072 - -
25–34 38(17.0) 184(83.0) 0.67(0.31, 1.46) 0.315 - -
35–44 26(16.8) 129(83.2) 0.68(0.30, 1.55) 0.366 - -
45–64 18(13.6) 115(86.4) 0.88(0.37, 2.08) 0.779 - -
> = 65 9(12.2) 65(87.8) 1 - - -
COR crude odds ratio, AOR adjusted odds ratio, CI Confidence interval
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of 21 ± 0.5 years. Most of study participants were in
the age group of 1–14 years (461, 33.9 %).
Prevalence of S. aureus
Of a total of 1360 clinical samples S. aureus was isolated
from (194, 14.3 %). Males had a higher isolation rate of
S. aureus than females (106, 16.2 %) versus (88, 12.5 %).
Rate of isolation of S. aureus was the highest in 15–24
years (46, 21.0 %). The isolation rate of S. aureus was not
significantly associated with sex [AOR, 95 % CI: 1.05(0.72,
1.53), p = 0.771] and age groups (p >0.05) (Table 1).
Isolation rate of S. aureus from clinical samples
In current study the major sources of S. aureus were
pus/abscess, ear discharge, blood, nasal swab and throat
swab which together, accounted for (175, 90.2 %) of all
isolates. The rest of the isolates were from urine, vaginal
discharge, eye swab, body fluid, stool and sputum,
accounting less than 10.0 % of the total. No S. aureus
was isolated from CSF (0/97) and urethral discharge (0/
19). The recovery rate of S. aureus was significantly
associated with pus [AOR, 95 % CI: 67.07(9.1,
493.8), p = 0.001], nasal swab [AOR, 95 % CI:
27(3.19, 228.05), p = 0.002], throat swab [AOR, 95 %
CI: 11.1(1.3, 94.37), p = 0.027] and ear discharge
[AOR, 95 % CI: 21.2(2.8, 162.3), p = 0.003] (Table 2).
Prevalence of MRSA
Out of 194 S. aurues recovered, (34, 17.5 %) were found
out to be MRSA and the remaining (160, 82.5 %) were
MSSA (Fig. 1). Relatively a higher number of MRSA
were isolated in males (19, 19.9 %) than in females (15,
17.0 %) and the highest number of MRSA were detected
in the age group 35–44 years (8, 30.8 %), followed by
age group 45–64 years (5, 27.8 %), above 64 years
(2, 22.2 %), 15–24 years (7, 17.4 %), 1–14 years (7,
Table 2 Isolation rate of S. aureus from clinical specimens at Yekatit 12 Hospital Medical College from September 2013 to April 2014,
Addis Ababa, Ethiopia
Specimen type Presence of S. aureus Total AOR 95 % CI P-value
Yes (N/%) No (N/ %) Na
Pus/abscess 118(55.4) 95(44.6) 213 67.074 (9.11, 493.8) 0.001**
Nasal swab 9(33.3) 18(66.7) 27 27.000 (3.19, 228.05) 0.002**
Throat swab 7(17.0) 34(83.0) 41 11.118 (1.31, 94.37) 0.027*
Vaginal discharge 3(2.5) 118(97.5) 121 1.373 (0.14, 13.50) 0.786
Urine 6(2.8) 211(97.2) 217 1.536 (0.18, 13.02) 0.694
Eye swab 2(12.5) 14(87.5) 16 7.714 (0.65, 91.32) 0.105
Blood 17(7.6) 206(92.4) 223 4.456 (0.58, 34.23) 0.151
Body fluids 4(5.3) 71(94.7) 75 3.042 (0.33, 28.0) 0.326
Stool 3(1.8) 168(98.2) 171 0.964 (0.09, 9.46) 0.975
Ear discharge 24(28.2) 61(71.8) 85 21.246 (2.78, 162.3) 0.003**
Sputum 1(0.8) 54 (98.2) 55 1 - -
AOR adjusted odds ratio
a Total sample
** Significant at P value < 0.01, * Significant at P value < 0.05
Fig. 1 Methicillin susceptibility pattern of S. aureus from participants at Yekatit 12 Hospital Medical College from September 2013 to April 2014,
Addis Ababa, Ethiopia
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14.6 %), and 25–34 years (4, 10.5 %). The isolation
rate of MRSA in relation to gender was not signi-
ficantly associated [COR, 95 % CI: 0.94(0.44, 1.98),
p = 0.87] as well as any of age groups (p >0.05)
(Table 3).
The major source of MRSA was pus (24/118), nasal
swab (3/9), ear discharge (3/24), throat swab (2/7) and
blood (2/17). No MRSA was observed in urine, stool,
body fluid, eye swab, sputum and vaginal discharge.
Blood (15, 88.2 %) had higher percentage of MSSA
followed by ear discharge (21, 87.5 %) and pus (94,
79.7 %). There was no statistical association between iso-
lation rates of MSRA with any of clinical samples (p >
0.05) (Table 4).
Antimicrobial susceptibility pattern of S. aureus
S. aurues isolated in this study were highly resistant to
penicillin (187, 96.4 %), trimethoprim-sulphamethoxazole
(103, 53.1 %), erythromycin (103, 53.1 %) and ciprofloxa-
cin (61, 31.4 %). On the contrary, lower resistant was man-
ifested by amoxicillin-clavulanate (36, 18.5 %), gentamicin
(26, 13.4 %), clindamycin (23, 11.9 %) and vancomycin
(10, 5.1 %) (Table 5).
All isolates were resistant to at least one antimicrobial
agent. MRSA isolates were 100 % resistant for penicillin,
erythromycin, trimethoprim-sulfamethoxazole, amoxicillin-
clavulanate, cefuroxime, cephalothin and least resistant for
vancomycin (10, 29.4 %). On the other hand, (153, 95.6 %)
of MSSA were resistant to penicillin. Being resistant/
susceptible for methicillin had a statistically significant
chance of being resistant/susceptible for amoxicillin-
clavulanate, cefuroxime and clindamycin (Table 6).
Multi-drug resistance (MDR) and Beta-lactamase
production pattern of S. aureus
Ninety-eight (50.5 %) of the isolates were multi-drug
resistance. According to Magiorakos et al. [15] MDR is
defined as non-susceptibility to at least one agent in
three or more antimicrobial categories. A higher number
of multi-drug resistances were observed in triple drugs
among penicillin G, erythromycin and trimethoprim-
sulfamethoxazole (18, 18.4 %), and quadruple drugs
among penicillin G, erythromycin, trimethoprim-
sulphamethoxazole and ciprofloxacin (13, 13.26 %).
Thirty (30.64 %) of multi-drug resistance was observed by
triple drugs. Penicillin resistant was seen in all multi-drug
resistant strains of S. aureus (Table 7). Of 194 S. aureus
isolates, (153, 79.0 %) were beta-lactamase producers.
Furthermore, of 34 MRSA isolates (30, 88.2 %) and out of
160 MSSA strains (123, 76.8 %) were produced beta-
lactamase.
Table 3 Association of methicillin resistant pattern of S. aureus in study participants with gender and age group at Yekatit 12
Hospital Medical College from September 2013 to April 2014, Addis Ababa, Ethiopia
Variable MRSA MSSA S. aureus COR 95 % CI P-value
N (%) N (%) N
Sex Male 19(19.9) 87(82.1) 106 0.94 (0.44, 1.98) 0.873
Female 15(17.0) 73(83.0) 88 1 - -
Age group <1 0(0) 9(100) 9 0.00 - 0.999
1–14 7(14.6) 41(85.4) 48 1.67 (0.29, 9.76) 0.567
15–24 8(17.4) 38(82.6) 46 1.36 (0.24, 7.78) 0.732
25–34 4(10.5) 34(89.5) 38 2.43 (0.37, 15.95) 0.356
35–44 8(30.8) 18(69.2) 26 0.64 (0.11, 3.80) 0.626
45–64 5(27.8) 13(72.2) 18 0.74 (0.11, 4.86) 0.757
> = 65 2(22.2) 7(77.8) 9 1 - -
COR crude odds ratio
Table 4 Association of methicillin resistant S. aureus to different
clinical specimens at Yekatit 12 Hospital Medical College from
September 2013 to April 2014, Addis Ababa, Ethiopia
Type of
specimen
MRSA MSSA Total COR 95 % CI P-value
N (%) N (%) Na
Pus/abscess 24(20.3) 94(79.7) 118 0.511 (0.11, 2.19) 0.366
Nasal swab 3(33.3) 6(66.7) 9 0.638 (0.11, 3.49) 0.605
Throat swab 2(28.6) 5(71.4) 7 0.000 - 0.999
Vaginal discharge 0(0) 3(100) 3 0.000 - 0.999
Urine 0(0) 6(100) 6 1.915 (0.41, 8.95) 0.409
Eye swab 0(0) 2(100) 2 0.000 - 0.999
Blood 2(11.8) 15(88.2) 17 0.000 - 0.999
Body fluids 0(0) 4(100) 4 0.000 - 0.999
Stool 0(0) 3(100) 3 0.000 - 1.000
Ear discharge 3(12.5) 21(87.5) 24 1.787 (0.49, 6.49) 0.378
Sputum 0(0) 1(100) 1 1 - -
COR crude odds ratio
a total S. aureus isolates from each type of sample
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Discussion
The present study showed that males had a higher isola-
tion rate of S. aureus than females. Rate of isolation of S.
aureus was also the highest in 15–24 years of age group.
Prevalence of MRSA in the present study, however, did
not vary significantly by gender (p = 0.87) and age group
(p > 0.05) and this is in agreement with earlier reports by
Geyid et al. [16] indicating that gender and age are not
risk factor for the acquisition or colonization of MRSA.
The prevalence of MRSA was found to be 17.5 % which
is less than that had been reported in Addis Ababa
[16, 17] and outside Addis Ababa [18]. Different
studies have depicted variations in the prevalence
rates of MRSA in different countries. Over 50 %
prevalence rate of MRSA was reported in Portugal
and Italy; 25 % in England, Greece and France; 2 %
in the Netherlands and Switzerland [19]. Prevalence
of MRSA ranged from 23.6 % in Australia to over
61 % in Taiwan and Singapore, and more than 70 %
in Japan and Hong Kong [20]. Differences in the
length of study period, number of study sites, sample
size, sample type and the laboratory procedures
employed may be factors that could contribute to var-
iations in the prevalence rate of MRSA [21]. The rate
of MRSA obtained in this study however, was nearly
the same as MRSA prevalence rate recorded in a
pan-European data that was obtained from studies
conducted among 43 laboratories from 10 European
countries [22].
Although no statistical association existed between
isolation rates of MSRA and MSSA with any of clinical
samples (p >0.05), the present study depicted that preva-
lence of MRSA and MSSA isolated from pus was the
highest as compared to other clinical samples. This find-
ing is in agreement with the result obtained in Ethiopia
[16, 18] and many similar studies [21, 23, 24] conducted
in other parts of the world. A highest isolation rate of S.
aureus in general and MRSA in particular in pus in our
study could partly be due to the fact that most of the
wound samples came from surgical wards and burn unit
of the hospital. MRSA on surgical wards is becoming in-
creasingly common especially in critically ill patients
who have spent prolonged periods on the intensive care
units [22, 23].
Even though this study was not designed to identify risk
factors for MRSA acquisition, risk factors that have
Table 5 Antimicrobial susceptibility pattern of S. aureus strains
to different antimicrobial agents at Yekatit 12 Hospital Medical
College from September 2013 to April 2014, Addis Ababa, Ethiopia
Antibiotics Resistant Susceptible
N (%) N (%)
Cefoxitin [30 μg] 34(17.5) 160(82.5)
Amoxicillin-clavulanate [30 μg] 36(18.5) 158(81.5)
Penicillin G [10 U] 187(96.4) 7(3.6)
Vancomycina 10(5.1) 184(94.9)
SXT [1.25/23.75 μg] 103(53.1) 91(46.9)
Chloramphenicol [30 μg] 36(18.6) 158(81.4)
Gentamycin [10 μg] 26(13.4) 168(86.6)
Cefuroxime [30 μg] 40(20.6) 154(79.4)
Clindamycin [30 μg] 23(11.9) 171(88.1)
Ciprofloxacin [5 μg] 61(31.4) 133(68.6)
Cephalothin [10 μg] 37(19.1) 157(80.9)
Erythromycin [15 μg] 103(53.1) 91(46.9)
SXT Trimethoprim-Sulfamethoxazole
a concentration from 2 μg/ml to16μg/ml
Table 6 Association of methicillin resistant and sensitive S. aureus to different antimicrobial classes at Yekatit 12 Hospital Medical
College from September 2013 to April 2014, Addis Ababa, Ethiopia
Antibiotics MRSA (n = 34) MSSA (n = 160) AOR 95 % CI P-value
N (%) N (%)
AMC [30 μg] 34(100) 2(1.3) 9.809 (1.56, 61.69) 0.015*
Penicillin G [10 U] 34(100) 153(95.6) 0.000 - 0.99
Vancomycina 10(29.4) 0(0) 0.000 - 0.99
SXT [1.25/23.75 μg] 34(100) 69(43.1) 16.24 (0.41, 63.28) 0.135
Chloramphenicol [30 μg] 16(47) 20(12.5) 1.130 (0.09, 13.63) 0.923
Gentamycin [10 μg] 13(38.2) 13(8.1) 0.896 (0.07, 10.98) 0.931
Cefuroxime [30 μg] 34(100) 6(3.8) 216.17 (10.8, 432.2) 0.001**
Clindamycin [30 μg] 18(53) 5(3.1) 13.22 (1.99, 87.62) 0.007**
Ciprofloxacin [5 μg] 28(82.5) 33(20.6) 0.615 (0.10, 3.73) 0.598
Erythromycin [15 μg] 34(100) 69(43.1) 9.044 (0.49, 16.05) 0.136
Cephalothin [10 μg] 34(100) 3(1.8) 1 - -
AMC Amoxilin- clavulanic acid, SXT Trimethoprim-Sulfamethoxazole
a concentration from 2 μg/ml to16μg/ml
** Significant at P value < 0.01, * Significant at P value < 0.05
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previously been associated with acquisition of MRSA in
hospitals such as broad-spectrum antimicrobial therapy,
admission to an intensive care unit, older age and
proximity to other patients with MRSA [25] could play a
major role in our study site. Antimicrobial susceptibility
test on all the 194 S. aureus isolates against 12 commonly
used antibiotics indicated that (187, 96.4 %) were resistant
to penicillin and this finding was in agreement with the
findings of Abera et al. [18]. The lowest drug resistant was
observed for vancomycin (10, 5.1 %). Furthermore, (98,
50.5 %) of the isolates were multi-drug resistant which is
consistent with a study in Ethiopia at Bahir Dar [18]. But
it was less than the results reported at Addis Ababa [16].
This variation could be explained in terms of periods of
study, hygienic practice of the population, difference in
socio-cultural and economic activity of the community.
All MRSA isolates encountered in this study were com-
pletely resistant (100 %) to antibiotics such as penicillin,
erythromycin and trimethoprim-sulfamethoxazole. Similar
results were noted for penicillin among MRSA strains in
India [26] and Trinidad & Tobago [21]. Unlike most stud-
ies in Ethiopia [16, 17] and elsewhere in the world [21, 27]
vancomycin resistance was very high. Ten (5.1 %) out of
194 S. aureus isolates were resistant to vancomycin and of
34 MRSA, (10, 29.4 %) were vancomycin resistant. A simi-
lar result was obtained for vancomycin resistance in previ-
ous reports in Trinidad [28], and Argentina, Brazil, Chile,
Mexico and Uruguay [29]. MRSA strains which were also
resistant to vancomycin in previous studies ranged from
none (0 %) in Ethiopia, Karachi and Uganda [16, 27, 30] to
8 % in Iran, Malaysia and Nigeria [31–33] which are lower
than the current study. A study in United States and Latin
American countries reported that most MRSA strains are
resistant to other antibiotics, thereby necessitating the use
of glycopeptides antibiotics, such as vancomycin. Treat-
ment failure has been incriminated as a cause of decreased
susceptibility of staphylococci to vancomycin [34]. Wise
use and continuous surveillance susceptibility testing of
MRSA against vancomycin have been reported as a rem-
edy to control reduced susceptibility of staphylococci to
vancomycin [35–37].
In the present study all S. aureus isolates were tested
for beta-lactamase production. It has been shown that
out of 194 isolates (153, 79.0 %) were beta-lactames pro-
ducers. Beta-lactamase producing strains of S. aureus in
the present study were much higher than that has been
reported by previous study conducted in Ethiopia [16]
but more or less the same as reported in India [38] and
Nigeria [14]. Our study further depicted that out of 34
MRSA strains (30, 88.2 %) produced beta-lactamase and
out of 160 MSSA strains (123, 76.8 %) were found out to
be beta-lactamase producers.
Conclusion
The prevalence of S. aureus and MRSA varies appre-
ciably based on type of clinical samples. Pus was the
main source of S. aureus and MRSA in the hospital
Table 7 Multi-drug resistance nature of S. aureus isolates at
Yekatit 12 Hospital Medical College from September 2013 to
April 2014, Addis Ababa, Ethiopia
Antibiotics Resistant strains
N %
P, E, SXT 18 18.40
P, G, E 5 5.10
P, C, SXT 4 4.08
P, C, CIP 3 3.06
P, CIP, E, SXT 13 13.26
P, G, C, E 3 3.06
P, G, C, SXT 2 2.04
P, CIP, E, SXT 1 1.02
P, AMC, E, SXT 1 1.02
P, FOX, G, SXT 1 1.02
P, FOX, E, SXT 2 2.04
P, C, CIP, E, SXT 2 2.04
P, G, CIP, AMC, SXT 1 1.02
P, G, CIP, E, SXT 1 1.02
P, G, C, E, SXT 1 1.02
P, CIP, E, SXT, DA 2 2.04
P, FOX, C, E, SXT 1 1.02
P, G, C, CIP, CXM, SXT 1 1.02
P, G, C, CIP, E, SXT 3 3.06
P, G, C, AMC, E, SXT 1 1.02
P, FOX, CIP, E, SXT, DA 3 3.06
P, FOX, C, E, CXM, SXT 2 2.04
P, G, C, CIP, E, SXT, DA 2 2.04
P, FOX, G, C, CIP, E, SXT 2 2.04
P, FOX, C, CIP, E, CXM, SXT 5 5.10
P, FOX, C, E, CXM, SXT, DA 1 1.02
P, FOX, CIP, AMC, KF, E, CXM 2 2.04
P, FOX, CIP, AMC, KF, SXT, DA 2 2.04
P, FOX, G, C, CIP, E, CXM, SXT 2 2.04
P, FOX, VAN, CIP,AMC, E, SXT, DA 5 5.10
P, FOX, VAN, CIP, AMC, E, CXM, SXT, DA 1 1.02
P, FOX, C, CIP, AMC, E, CXM, SXT, DA 1 1.02
P, FOX, VAN, CIP, AMC, KF, E, SXT, DA 1 1.02
P, FOX, VAN, G, C, CIP, AMC, E, SXT, DA 1 1.02
P, FOX, VAN, G, C, CIP, AMC, E, CXM, SXT, DA 2 2.04
Total 98 100.00
P Penicillin G, CIP Ciprofloxacin, AMC Amoxicillin-clavulanic acid, C Chloramphenicol,
FOX Cefoxitin, KF Cephalothin, E Erythromycin, G Gentamycin, VAN Vancomycin, SXT
Trimethoprim-sulphamethoxazole, DA Clindamycin, CXM Cefuroxime
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settings. The prevalence of MRSA stains obtained in this
study was low when compared with the prevalence rates
obtained in previous studies conducted in Ethiopia.
However, the prevalence rate was considerably high
when compared to other similar studies conducted else-
where. MRSA strains were multidrug-resistant and un-
usually high numbers of isolates were resistant to
vancomycin, the drug of choice for treating multidrug
resistant MRSA infections. Reducing this burden by
good infection control practices such as strict hand
washing, identifying MRSA carriers and treating them as
well as prudent use of antimicrobial agents is recom-
mended. Further, genotypic studies are also needed to
establish and characterize resistant strains of S. aureus.
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